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Background: During EGFR internalization CIN85 bridges EGFR-Cbl complex, endocytic machinery and fusible
membrane through the interactions of CIN85 with c-Cbl, endophilins and phosphatidic acid. These protein-protein
and protein-lipid interactions are mediated or regulated by the positively charged C-terminal coiled-coil domain of
CIN85. However, the details of CIN85-lipid interaction remain unknown. The present study suggested a possible
electric interaction between the negative charge of phosphatidic acid and the positive charge of basic amino acids
in coiled-coil domain.
Results: Mutations of the basic amino acids in the coiled-coil domain, especially K645, K646, R648 and R650, into neutral
amino acid alanine completely blocked the interaction of CIN85 with c-Cbl or phosphatidic acid. However, they did not
affect CIN85-endophilin interaction. In addition, CIN85 was found to associate with the internalized EGFR endosomes. It
interacted with several ESCRT (Endosomal Sorting Complex Required for Transport) component proteins for ESCRT
assembly on endosomal membrane. Mutations in the coiled-coil domain (deletion of the coiled-coil domain or point
mutations of the basic amino acids) dissociated CIN85 from endosomes. These mutants bound the ESCRT components in
cytoplasm to prevent them from assembly on endosomal membrane and inhibited EGFR sorting for degradation.
Conclusions: As an adaptor protein, CIN85 interacts with variety of partners through several domains. The positive
charges of basic amino acids in the coiled-coil domain are not only involved in the interaction with phosphatidic acid,
but also regulate the interaction of CIN85 with c-Cbl. CIN85 also interacts with ESCRT components for protein sorting in
endosomes. These CIN85-protein and CIN85-lipid interactions enable CIN85 to link EGFR-Cbl endocytic complex with
fusible membrane during EGFR endocytosis and subsequently to facilitate ESCRT formation on endosomal membrane for
EGFR sorting and degradation.
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CIN85 is identified as a Cbl-interacting protein of 85 kDa
and belongs to adaptor/scaffold proteins [1,2]. It consists of
three Src homology (SH3) domains, a proline-rich region
and a putative α-helical coiled-coil domain at the extreme
C-terminal end [1]. As an adaptor protein, CIN85 is in-
volved in Cbl-dependent EGFR internalization, intracellular* Correspondence: kliao@sibs.ac.cn
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unless otherwise stated.receptor trafficking, sorting and degradation [3-8]. How-
ever, the detailed mechanisms by which CIN85 mediates
EGFR endocytic process are not fully defined.
The activation of EGFR by EGF leads to the binding and
ubiquitylation of the receptor by c-Cbl, which then recruits
CIN85 to EGFR-Cbl complex to initiate the receptor endo-
cytosis [3,9-11]. CIN85, on the other hand, constitutively
binds to endophilins, the regulatory proteins that control
endocytosis through clathrin-coated pits [3,4,12,13]. Thus,
CIN85 tethers EGFR-Cbl complex to the endocytic machin-
ery in an EGF-dependent manner [1]. After internalization,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CIN85 mono-ubiquitylation in endosomes [6,14]. The ubi-
quitylated EGFR is then sorted into multivesicular bodies
and fused into lysosomes for degradation [15-17].
EGFR internalization and degradation is enhanced by
overexpression of either phospholipase D1 or D2, and
inhibited by expression of inactive phospholipase D mu-
tants or by treatment of cells with primary alcohols [18].
The function of phospholipase D in facilitating mem-
brane endocytosis has largely been attributed to its abil-
ity to generate phosphatidic acid, a fusogenic lipid that
lowers the activation energy required for inward curving
of membrane [19,20]. Upon EGF stimulation, phospho-
lipase D is activated in plasma membrane and the pro-
duction of phosphatidic acid, which enhances membrane
fusibility for endocytosis, is increased [19,21].
In our previous study, it is identified that CIN85 binds
to phosphatidic acid [22]. This ability enables CIN85 to
target phosphatidic acid-enriched membrane. By interact-
ing with EGFR-Cbl complex, endophilins and phospha-
tidic acid, CIN85 acts as a mediator to bring the receptor,
endocytic machinery and fusible membrane together. It is
further identified that deletion of the coiled-coil domain
blocks CIN85-phosphatidic acid interaction, weakens
CIN85-Cbl interaction, dissociates CIN85 from membrane
and reduces EGFR degradation [22].
The coiled-coil domain is well-known for its ability to
form oligomers in coiled-coil domain-containing proteins,
including CIN85 [22-24]. By adding chemical cross-linking
reagents, CIN85 is found to form oligomers through its
coiled-coil domain [22,23]. Of 70 amino acid residues in
the coiled-coil domain, 16 residues are basic amino acids
(K or R) [2]. The basic amino acid frequency (23%) is much
higher than that in an average protein. Because phosphatidic
acid is a negatively charged lipid, the CIN85-phosphatidic
acid interaction could be mediated by electric interaction
between the negative charge of the lipid and the positive
charge of basic amino acids in coiled-coil domain.
In the present study, we found that the basic amino
acids in the coiled-coil domain were essential for CIN85-
phosphatidic acid interaction. Of 16 K and R residues in
the coiled-coil domain, K645, K646, R648 and R650 were
the most important. The alanine mutation of these 4 basic
amino acids inhibited CIN85-phosphatidic acid inter-
action, impaired the recruitment of CIN85 by c-Cbl, disso-
ciated CIN85 from EGFR endosomes and reduced EGFR
degradation.
Results
K645, K646, R648 and R650 in coiled-coil domain are
essential for CIN85-phosphatidic acid interaction and
membrane association
It was previously identified that the interaction of CIN85
with phosphatidic acid required the C-terminal coiled-coil domain [22]. In fact, coiled-coil domain alone was
sufficient to bind phosphatidic acid (Figure 1A). In total
70 amino acid residues of coiled-coil domain there are 11
lysine and 5 arginine residues (Figure 1B). The enriched
basic amino acid composition enables the coiled-coil do-
main to be positively charged in a neutral pH environment
and interact with negatively charged proteins or lipids.
These 16 basic amino acids naturally form 5 clusters,
which were divided into 4 groups for generating muta-
tions: Group C includes K596, K598, K613, R617 and
R620; Group B K627, K631, R632 and K635; Group A
K645, K646, R648 and R650; Group D K659, K660 and
K665 (Figure 1B). They were mutated into alanine, a
neutral amino acid, to verify which of these basic amino
acids are involved in CIN85-phosphatidic acid interaction
(Figure 1B). The mutation of all 16 basic amino acids
(CIN85-16m) completely blocked CIN85-phosphatidic
acid interaction (Figure 1C). It also inhibited CIN85
oligomerization or the association of CIN85 with mem-
brane vesicles (Figure 1D and E). Essentially, mutation of
these 16 basic amino acids exhibited the same effect as
deletion of the coiled-coil domain (Figure 1).
Mutations of the basic amino acids in individual groups
revealed that the basic amino acids in Group A (K645,
K646, R648 and R650) were the most important for coiled-
coil domain (Figure 1C, D and E). Mutation of these 4 basic
amino acids (CIN85-A4m) exhibited the same inhibitory
effect as mutation of all 16 basic amino acids. Mutations in
other groups (CIN85-C5m, B4m and D3m) did not affect
or only partially inhibited the interaction of CIN85 with
phosphatidic acid (Figure 1C).
The association of CIN85 with membrane vesicles was
most likely mediated by its interaction with phosphatidic
acid (Figure 1C and D). Mutations that inhibited CIN85-
phosphatidic acid interaction also disrupted CIN85-
membrane vesicle association (Figure 1C and D). In fact,
CIN85 only associates with liposome containing phospha-
tidic acid (10%) and phosphatidyl choline (90%), but not
liposome of phosphatidyl choline alone [22]. The associ-
ation with membrane might also facilitate the alignment
of CIN85 molecules on membrane surface, enabling them
to oligomerize (Figure 1E).
Further dissection of the basic amino acids in Group A
revealed that the presence of positive charges in this group
was more important than the position of these positive
charges. Mutations of 2 basic amino acids (K645/646A),
(K646/R648A) or (R648/650A) did not affect phosphatidic
acid binding, membrane association or oligomerization
(Figure 2). Mutations of 3 basic amino acids had mixed ef-
fect on the coiled-coil domain. Mutation of K646, R648 and
R650 did not affect phosphatidic acid binding, membrane
association or oligomerization, whereas mutation of K645,
K646 and R648 inhibited these functions (Figure 2B-D).
In addition, mutation of either one of these four basic
Figure 1 K645, K646, R648 and R650 in coiled-coil domain are essential for CIN85-phosphatidic acid interaction and membrane
association. (A) Interaction of the coiled-coil domain with phosphatidic acid. The coiled-coil domain (CC) and the C-terminal fragment (PRC)
were eGFP-tagged, expressed and purified from HEK293 cells to blot PIP StripTM membrane. The phospholipids on the PIP StripTM membrane are:
1, lysophosphatidic acid; 2, lysophosphatidylcholine; 3, phosphatidylinositol; 4, PtdIns(3)P; 5, PtdIns(4)P; 6, PtdIns(5)P; 7, phosphatidylethanolamine;
8, phosphatidylcholine; 9, sphingosine 1-phosphate; 10, PtdIns(3,4)P; 11, PtdIns(3,5)P; 12, PtdIns(4,5)P; 13, PtdIns(3,4,5)P; 14, phosphatidic acid; 15,
phosphatidylserine; 16, blank. (B) The point mutations of the basic amino acids in the coiled-coil domain and other truncation mutations. The 16
basic amino acids in coiled-coil domain were divided into 4 groups (C5, B4, A4 and D3) and were mutated to alanine (A). (C) Interaction of CIN85
mutants with phosphatidic acid. Phosphatidic acid (PA) was dotted on nitrocellulose membrane at 1 and 10 nmole. The Western blot showed the
relative protein level of each mutant used to blot the phosphatidic acid membrane. The mutants were Flag-tagged. (D) The association of CIN85
mutants with intracellular membrane vesicles. M, the membrane fraction of ultracentrifugation; C, the cytosolic fraction of ultracentrifugation.
(E) Chemical cross-link of CIN85 mutants by dimethylpimelimidate (DMP). +DMP, cell lysate was treated with DMP; −DMP, control cell lysate. The
numbers indicate the molecular weight markers.
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shown). Overall, there was no single basic amino acid in
K645, K646, R648 and R650 that was more prominent
than the others.K645, K646, R648 and R650 are required for the
recruitment of CIN85 by EGFR endocytic complex
EGFR endocytosis requires the coordinated interaction
among the receptor complex, endocytic machinery and
membrane. As an adaptor protein, CIN85 is recruited by
c-Cbl to EGFR-Cbl complex [3]. The interaction of CIN85
with c-Cbl is mediated by SH3 domains in CIN85 [22,23].
No direct interaction between c-Cbl and the coiled-coil
domain of CIN85 has been identified [22]. Although the
coiled-coil domain did not interact with c-Cbl, deletion ofthis domain led to the impairment of CIN85-Cbl inter-
action (Figure 3A).
Because the basic amino acids in coiled-coil domain
were involved in CIN85-lipid interaction (Figure 1), their
role in CIN85-Cbl interaction was investigated. As shown
in Figure 3A, mutations of the basic amino acids had
strong inhibitory effect on CIN85-Cbl interaction. Except
mutation in Group B (CIN85-B4m), which did not affect
CIN85-Cbl interaction, all the other mutations (CIN85-
16m, A4m, C5m and D3m) inhibited CIN85-Cbl inter-
action (Figure 3A). For most CIN85 mutants, the effect on
CIN85-Cbl interaction was parallel to that on CIN85-
phosphatidic acid interaction. CIN85-16m, A4m and D3m
affected both phosphatidic and c-Cbl binding, while
CIN85-B4m inhibited neither of them (Figure 1C and 3A).
CIN85-C5m was the only exception that it inhibited the
Figure 2 The net positive charges in group A (K645, K646, R648 and R650) are more important than their positions. (A) The construction
of point mutations in group A. (B) Interaction of the mutants with phosphatidic acid. (C) The association of the mutants with intracellular membrane
vesicles. (D) Chemical cross-link of CIN85 mutants by dimethylpimelimidate (DMP). The labels in this figure are the same as in Figure 1.
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and 3A).
Through the constitutive CIN85-endophilin interaction,
CIN85 links EGFR-Cbl complex with endocytic machinery
of clathrin-coated pits [3,13]. Because CIN85-endophilin
interaction is mediated by the C-terminal part of CIN85,
deletion of coiled-coil domain might disrupt the endophilin
interacting region in CIN85 C-terminus [3]. That was the
case as deletion of the coiled-coil domain disrupted CIN85-
endophilin interaction (Figure 3B). The less disruptive point
mutations of the basic amino acids in coiled-coil domain
revealed that CIN85-endophilin interaction was independ-
ent from the positive charge in coiled-coil domain. There
was no difference for endophilin to interact with CIN85,
CIN85-A4m, CIN85-B4m or other mutants (Figure 3B).
Since CIN85 is recruited by c-Cbl in EGFR-Cbl complex,
the interaction between CIN85 and c-Cbl should not affect
EGFR-Cbl complex. As shown in Figure 3C, no matter
whether the mutants could interact with c-Cbl (CIN85-
B4m) or not (CIN85-ΔCC or CIN85-A4m), the presence of
CIN85 mutants had no effect on EGFR-Cbl interaction.
Mutation of K645, K646, R648 and R650 dissociates CIN85
from EGFR endosomal membrane and affects the protein
sorting process
In COS7 cells expressing CIN85 null-function mutant
(CIN85-ΔCC or CIN85-A4m), EGF-stimulated EGFRdegradation was decreased, whereas in cells expressing
neutral mutant (CIN85-B4m) or wild type CIN85 the
ligand-stimulated receptor degradation was not affected
(Figure 3D and E). However, no difference in EGFR internal-
ization was observed in COS7 cells expressing eGFP, CIN85
or CIN85 mutant (neutral or null-function) (Figure 4A).
Thus, the expression of CIN85 null-function mutant did
not inhibit the receptor internalization per se (Figure 4A).
It only reduced the degradation of the internalized EGFR
(Figure 3D and E). The inhibition of EGFR degradation
but not EGFR internalization suggested that these CIN85
null-function mutants interfere with EGFR sorting/deg-
radation process.
After EGFR internalization, CIN85 or the neutral mu-
tant CIN85-B4m was found to be associated with EGFR
endosomes (Figure 4A). Both of them exhibited similar
endosome binding (Figure 4B). In contrast, CIN85 null-
function mutants (CIN85-ΔCC, CIN85-16m or CIN85-
A4m) did not associated with EGFR endosomes (Figure 4A
and B). The internalized EGFR is sorted by the assembly
of ESCRT (Endosomal Sorting Complex Required for
Transport) on endosomal membrane [25]. Vps (vacuolar
protein sorting) is a group of ESCRT components that are
recruited to endosomal membrane by adaptor proteins
[26]. It is possible that CIN85 on endosomal membrane
interacts with these ESCRT components to facilitate
ESCRT assembly.
Figure 3 The mutation of K645, K646, R648 and R650 disrupts CIN85-Cbl interaction and inhibits EGFR degradation. (A) Interaction of
CIN85 mutants with c-Cbl. HA-tagged c-Cbl and Flag-tagged CIN85 mutants were co-expressed in HEK293 cells and HA-Cbl was immunoprecipitated
by anti-HA antibody (IP: α-HA-Cbl). CIN85 mutants were detected by immunoblot with anti-Flag antibody (IB). (B) Interaction of CIN85 mutants with
endophilins. CIN85 mutants were expressed in COS7 cells and endogenous endophilins were immunoprecipitated by anti-endophilin antibody. (C)
Interaction of EGFR and c-Cbl in the presence of CIN85 mutants. COS7 cells co-expressing CIN85 mutant and HA-Cbl were serum starved and
stimulated with 25 ng/ml EGF for 30 minutes. HA-Cbl was immunoprecipitated by anti-HA antibody. CIN85 mutants and EGFR were detected by
immunoblot with anti-Flag antibody and anti-EGFR antibody respectively. (D) Inhibition of EGFR downregulation by CIN85-ΔCC or CIN85-A4m. COS7
cells transfected with CIN85, CIN85-ΔCC, CIN85-A4m, CIN85-B4m or blank vector were serum starved and stimulated with 25 ng/ml EGF for indicated
times (0, 15, 30, 60, 120, 180 min). Cells were harvested and EGFR was detected by Western blot. Tubulin was used as loading control. (E) Image gray
statistical plot of EGFR downregulation in Figure 3D. Each gray level of EGFR electrophoretic band was normalized against relative EGFR level at 0 min.
The final data were averaged from two independent western blot assays.
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localized with Vps4, Vps4m and CHMP4B (Vps32B) [22].
Moreover, coiled-coil domain deletion (CIN85-ΔCC) did
not affect their cellular co-localization (Figure 5D-F). Therewere also protein interactions between CIN85 and Vps4,
Vps4m and CHMP4B (Vps32B) (Figure 5A and B). Vps4 is
a cytoplasmic ATPase that is recruited to ESCRT-III to
regulate ESCRT dissociation [27]. It weakly interacted with
Figure 4 The mutation of K645, K646, R648 and R650 dissociates CIN85 from EGFR endosome. (A) EGF endocytosis analysis in eGFP/
eGFP-CIN85 mutants transfected COS7 cells. COS7 cells expressing eGFP-tagged CIN85 mutant were incubated with 200 ng/ml Alexa Fluor 647
labeled EGF for 30 min on ice and then shifted to 37°C. At indicated time the cells were fixed and immunostained with anti-EGFR antibody.
EGFP-tagged CIN85 mutant was visualized by eGFP fluorescence and the labeled EGF was visualized by the fluorescence of Alexa Fluor 647. A
selected area is enlarged 6 times to reveal the details. The arrows point the white dots which are the colocalization of EGF (purple), EGFR (red)
and eGFP-CIN85 mutant (green). The bar is 10 μm. (B) Plot of the percentage of EGF-EGFR endosomes with eGFP-CIN85 or mutant association.
For each mutant, 10 cells were used to calculate white dots and total EGF-EGFR endosomes, and the percentage was normalized against the
average percentage in eGFP-CIN85 expressing cell. Student’s t-test was performed. The P values between eGFP-CIN85 expressing cells and eGFP
expressing cells or eGFP-CIN85 mutants expressing cells were ***9.34E-05 (10 min) and ***0.000272 (20 min) for eGFP; ***0.000187 (10 min) and
**0.001979 (20 min) for eGFP-ΔCC; ***0.000252 (10 min) and **0.007448 (20 min) for eGFP-16 m; **0.001818 (10 min) and **0.002121 (20 min)
for eGFP-A4m; 0.329283 (10 min) and 0.739651 (20 min) for eGFP-B4m.
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tant, Vps4m that constitutively associates with endosomal
membrane [28], dramatically increased its interaction with
CIN85 (Figure 5B). For both Vps4 and Vps4m, their inter-
action with CIN85 or cellular co-localization was independ-
ent from the coiled-coil domain (Figure 5B,C,E and F).
In addition, Vps4m appeared to be associated withintracellular membrane vesicles, whereas the wild type
Vps4 was mostly cytoplasmic protein (Figure 6B).
There was only weak interaction between CIN85 and
CHMP4B (Figure 5A and C), although they were co-
localized in cells (Figure 5D) [22]. In comparison to the in-
teractions with other ESCRT proteins [Vps4m, CHMP2A
(Vps2A) and CHMP4C (Vps32C)], CIN85-CHMP4B
Figure 5 Interactions of CIN85 with Vps proteins. (A) Interactions of CIN85 and CIN85-ΔCC with CHMP4B. Flag-tagged CIN85 and eGFP-tagged
CHMP4B were co-expressed in HEK293 cells and Flag-CIN85 was immunoprecipitated by anti-Flag antibody. CHMP4B in immunoprecipitated sample
was detected by Western blot. (B) Interactions of CIN85 and CIN85-ΔCC with Vps4 and Vps4m (ATPase negative mutant). Flag-tagged CIN85 and
eGFP-tagged Vps4 were co-expressed in HEK293 cells and Flag-CIN85 was immunoprecipitated by anti-Flag antibody. Vps4 in immunoprecipitated
sample was detected by Western blot. (C) Interactions of CIN85 and CIN85-ΔCC with different Vps proteins. The tagged CIN85 and Vps protein were
co-expressed in HEK293 cells and CIN85 was immunoprecipitated. Vps proteins were detected by Western blot. (D) Co-localization of CIN85 and
CIN85-ΔCC with CHMP4B. Flag-tagged CIN85 was co-expressed with eGFP-tagged CHMP4B in HEK293 cells. Cells were fixed with 4% PFA and observed
by confocal microscopy. Τhe bar is 10 μm. (E, F) Co-localization of Flag-tagged CIN85 and CIN85-ΔCC with eGFP-tagged Vps4 and Vps4m.
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CHMP4B was co-precipitated with either CIN85 or
CIN85-ΔCC (Figure 5A). On the other hand, CHMP2A
(Vps2A) and CHMP4C (Vps32C), two core members in
ESCRT-III that are assembled in sequential manner on
endosomal membrane, interacted with CIN85 strongly
(Figure 5C).
In ESCRT complex not all the components are in simi-
lar position to contact with CIN85 [25]. The domains of
CIN85 involved in the interaction varied with different
Vps proteins. The interaction of CIN85 with CHMP2A
was mediated by the C-terminus containing the proline-
rich region, as CHMP2A was colocalized with CIN85 C-terminus, but not N-terminal SH3 domains (Figure 6C).
In contrast, the interaction between CIN85 and Vps4
was most likely mediated by the N-terminal SH3 do-
mains (Figure 6D). Vps4m was colocalized with N-
terminal SH3 domains, but not C-terminus containing
the proline-rich region (Figure 6D). Whatever the dif-
ferences were in the interactions between CIN85 and
Vps proteins, they were all independent from the
coiled-coil domain (Figure 5C). As CIN85 with muta-
tions in coiled-coil domain (CIN85-ΔCC, CIN85-16m
or CIN85-A4m) dissociated from EGFR endosomes,
their interaction with Vps proteins in cytoplasm pre-
vented the Vps proteins to interact with EGFR-Cbl-
Figure 6 Cellular colocalization of Vps4 and CHMP2A with CIN85 domains. Τhe bar is 10 μm. (A) Construction of fusion proteins of CIN85
fragment. CIN85 fragment was tagged with eGFP. (B) Intracellular localization of Vps4 and Vps4m (ATPase negative mutant). The proteins were tagged
with DsRed and expressed in HEK293 cells. (C) Colocalization of CIN85 fragment with CHMP2A. EGFP-tagged CIN85 mutant and DsRed-tagged CHMP2A
were co-expressed in HEK293 cells. The proteins were visualized by the tagged fluorescence protein. (D) Colocalization of CIN85 fragment with Vps4m.
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presence of exogenous CIN85 mutants interfered with
EGFR sorting process in endosomes and less EGFR was
sorted to lysosome for degradation.
Discussion
The recruitment of CIN85 by c-Cbl in EGFR-Cbl com-
plex has been indicated as the initial step for EGFR in-
ternalization [3]. The interaction of CIN85 with c-Cbl is
mediated by the SH3 domains in CIN85 and a novel
proline-arginine motif present in the distal carboxyl-
terminus of Cbl [3,22,23,29]. Interestingly, c-Cbl can
bind to wild type CIN85 or CIN85 fragment containing
only the SH3 domains (CIN85-SH3), but cannot bind to
CIN85 with coiled-coil domain deletion (CIN85-ΔCC)
[3,22]. The SH3 domains in CIN85-ΔCC appear to be
blocked for c-Cbl interaction, possibly due to the con-
formational change in CIN85 lacking the coiled-coil do-
main [30]. However, the detailed mechanism by which
the deletion of coiled-coil domain affects CIN85-Cbl
interaction is still not clear. It is possible that without
coiled-coil domain the proline-rich region in CIN85 may
engage in auto-interaction with the SH3 domains to pre-
vent them to bind c-Cbl [31]. The difference of CIN85-
SH3 and CIN85-ΔCC in c-Cbl binding leads to different
effects on EGFR internalization. CIN85-SH3 has adominant negative effect on EGF stimulated EGFR in-
ternalization [11], whereas CIN85-ΔCC exhibits no in-
hibitory effect on EGFR internalization (Figure 4). The
interaction of CIN85-SH3 with c-Cbl competes off the
binding of functional CIN85 to EGFR-Cbl complex. Due to
the lack of C-terminal endophilin-interacting domains,
CIN85-SH3 cannot tether EGFR-Cbl complex with endocy-
tic machinery, blocking endophilin-mediated EGFR endo-
cytosis. CIN85-ΔCC, on the other hand, cannot interact
with c-Cbl and is a bystander to EGFR-Cbl complex. The
endogenous CIN85 can still be recruited by c-Cbl to form
EGFR-Cbl-CIN85 complex, which then recruits endocytic
proteins for receptor internalization. Thus, binding of
CIN85 mutant to c-Cbl is essential for the dominant nega-
tive inhibition of EGFR internalization.
The point mutations in the coiled-coil domain minimize
the disruptive effect of protein truncation [22]. In fact, the
point mutation of the basic amino acids in the coiled-coil
domain (CIN85-16m) is sufficient to disrupt CIN85-Cbl
interaction (Figure 3A). It not only inhibits CIN85-Cbl
interaction, but also blocks CIN85-phosphatidic acid inter-
action (Figures 1 and 3). The results from the mutations of
basic amino acids in coiled-coil domain support the electric
charge interaction between phosphatidic acid and CIN85
(Figure 1). K645, K646, R648 and R650 out of 16 basic
amino acids in coiled-coil domain are the most important
Figure 7 Illustration of EGFR endocytosis process. The functions
of CIN85 during EGFR internalization and sorting are depicted in this
illustration. It is not a comprehensive model for EGFR endocytosis
process, rather a model for understanding the functions of CIN85 in
EGFR endocytosis process. PA, phosphatidic acid; endo-complex,
endophilins and endocytic protein complex; MVB,
multi-vesicular bodies.
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Cbl interaction (Figure 1 and 3). Mutation of these four
basic amino acids (CIN85-A4m) is sufficient to disrupt
every CIN85 interactions except CIN85-endophilin inter-
action (Figure 3B).
The interactions with c-Cbl and phosphatidic acid enable
CIN85 to couple EGFR endocytic complex with fusible
membrane. The results from study of phospholipase D acti-
vation and EGFR endocytosis support this kind of associ-
ation, since EGF stimulation induces the activation of
phospholipase D as well as EGFR internalization [18]. Phos-
phatidic acid is generated by phospholipase D in response
to EGF or other growth factors [19-21]. The activation of
phospholipase D increases phosphatidic acid concentration
in plasma membrane, while the stimulation of EGFR trig-
gers the c-Cbl binding to initiate the endocytic complex
formation [3]. By bridging these two events, CIN85 facili-
tates the endocytic complex formation at membrane area
enriched with fusogenic lipid.
Reports have shown that knockdown of CIN85 by RNA
interference has no significant effect on EGFR internalization,
but rather delays the degradation of internalized EGFR [8,11].
It is further identified that the internalized EGFR is recycled
rather than degraded in CIN85-depleted cells [11]. Depletion
of CIN85 shifts the trafficking of internalized EGFR from the
degradative to the recycling pathway. It seems to be that
CIN85 is required for the sorting of the internalized EGFR.
And CIN85 independent endocytic pathways are involved in
EGFR internalization in CIN85-depleted cells.
After EGFR internalization, CIN85, associated to
EGFR-Cbl complex, appears on endosomal membrane
(Figure 4). Its interaction with ESCRT components will
facilitate the assembly of ESCRT on endosomal membrane
(Figure 5). CIN85 mutants (CIN85-ΔCC, CIN85-16m and
CIN85-A4m) that do not bind to c-Cbl or phosphatidic
acid lose their ability to associate with EGFR-positive
endosomes (Figure 4). These mutants, however, can still
interact with ESCRT components in cytoplasm, equivalent
to depleting ESCRT components for assembly on endoso-
mal membrane and resulting in the inhibition of EGFR
sorting for degradation (Figure 5). Similar result has been
obtained by knocking down ESCRT protein. For example,
the depletion of CHMP3 (Vps24, a component of ESCRT-
III) in mammalian cells severely inhibits EGFR degrad-
ation, but the termination of EGFR membrane signal re-
mains unaffected [32].
As an adaptor protein, CIN85 acts as a mediator in
EGFR endocytosis and sorting process. Its ability to
interact with multiple proteins and fusogenic lipid also
makes CIN85 a mediator between proteins and lipid.
Membrane receptor endocytosis, sorting and degrad-
ation are events of coordinated protein and membrane
interactions. CIN85 appears to be an important match-
maker in these events (Figure 7).Conclusions
During EGFR endocytosis, CIN85 tethers EGFR, phos-
phatidic acid and clathrin-coated pits to facilitate the re-
ceptor internalization. The interaction of CIN85 with
EGFR-Cbl complex and phosphatidic acid targeted the
internalized proteins to membrane areas enriched with
fusogenic lipid. The coiled-coil domain, especially the
basic amino acids in the domain, is the key regulatory
element for the interactions of CIN85 with EGFR-Cbl as
well as phosphatidic acid. After endocytosis, CIN85 in
association with EGFR-Cbl complex on endosomal
membrane recruits several ESCRT components to endo-
some for ESCRT assembly. Then the ESCRT complex on
endosomal membrane induces the formation of multi-




All results of this research were based on cultured
HEK293 or COS7 cells lines. Neither human (human
subjects, human material or human data) nor animals
(vertebrates or any regulated invertebrates) were used in
this experimental research.
Materials
Anti-EGFR, anti-Cbl and anti-endophilins antibodies were
purchased from Santa Cruz. Anti-CIN85 monoclonal anti-
body was from Upstate. Anti-flag monoclonal antibody,
phosphatidic acid, DMP (dimethylpimelimidate) and horse
radish peroxidase-conjuated secondary antibodies were
from Sigma. EGF, Alexa Fluor 647 labeled EGF, PIP Strips™
membrane and fluorescence labeled secondary antibodies
(Alexa Fluor 488/546 conjugates) for immunofluorescence
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scanning confocal microsystem, including the leica TCS
SP2 confocal microscope, Leica confocal scanner, and Leica
confocal acquisition software were used with the HCX PL
APO 1bd. BL 63.0 X/1.4 oil objective at 1.4 numerical aper-
ture at a working temperature of 22°C.
Plasmids construction
The truncation and point mutations of CIN85 were
constructed by polymerase chain reaction amplification
and the mutants were tagged with Flag-tag or eGFP at the
N-terminus of the fusion protein. CIN85-ΔCC was the de-
letion of amino acid 601 to 665. CIN85-PRC was the
fragment of amino acid 334 to 665. CIN85-CC was the
coiled-coil domain of amino acid 594 to 665. CIN85-
SH3 was the N-terminus of amino acid 1 to 331. The
16 basic amino acids in CIN85 from amino acid 596
to 665 (K596, K598, K613, R617, R620, K627, K631,
R632, K635, K645, K646, R648, R650, K659, K660 and
K665) were divided into several groups and mutated
to alanine residues.
Protein expression, immunofluorescence staining,
immunoprecipitation and western blot
CIN85 mutant plasmid was transiently transfected into
HEK293 or COS7 cells and experiments were performed in
48 hours. For immunofluorescence staining, cells were fixed
in 4% paraformaldehyde (PFA) in phosphate buffered saline
(PBS). EGFP fusion proteins and Fluor-labeled EGF were
directly visualized by confocal microscope. Other proteins
were stained with appropriate primary antibodies and
Fluor-labeled secondary antibodies. For immunoprecipita-
tion, two plasmids in 1:3 ratio (primary immunoprecipi-
tated protein/co-precipitated protein) were co-transfected
into cells and the cells were lysed in a buffer containing 1%
Triton X-100, 10% glycerol, 20 mM Hepes, pH7.4, 150 mM
NaCl, 1 mM EDTA, 1 mM PMSF and 2 μl/ml protease
inhibitor cocktails 1 and 2. The immunoprecipitation and
western blots were conducted as described previously [33].
Cell fractionation for intracellular membrane vesicles
Cells were homogenized in isotonic buffer containing
20 mM Hepes, pH 7.4, 0.25 M sucrose, 1 mM EDTA,
2.5 mM dithiothreitol, 1 mM PMSF and 2 μl/ml protease
inhibitor cocktails 1 and 2. The homogenized cell lysate
was centrifuged at 12,000 × g for 15 min. The pellet was
discarded and the supernatant was then ultracentrifuged
at 100,000 × g for 90 minutes to separate intracellular
membrane vesicles and cytoplasm.
Phosphatidic acid association
The eGFP-tagged CIN85-PRC or CIN85-CC was expressed
in HEK293 cells and purified by immunoprecipitation. The
immunopurified fusion protein was incubated with PIPStripsTM following the manufacturer’s instruction and
detected by immunoblot with anti-eGFP antibody. The
phosphatidic acid membrane was prepared by dotting
nitrocellulose membrane with phosphatidic acid in chloro-
form solution. CIN85 mutants expressed in HEK293 cell
were prepared by homogenizing the cell in buffer contain-
ing 20 mM Hepes, pH7.4, 150 mM NaCl, 2 mM MgCl2,
15 mM KCl, 1 mM EDTA, 1 mM PMSF and 2 μl/ml prote-
ase inhibitor cocktails 1 and 2. The mixture was then cen-
trifuged at 12,000 × g for 15 min and the supernatant was
used to blot the phosphatidic acid membrane. The proteins
were detected by anti-Flag antibody.
Downregulation and internalization of EGFR
COS7 cells were transfected with CIN85 mutant plasmid,
serum-starved and stimulated with 25 ng/ml EGF. The
cells were harvested at various time points and EGFR
protein was detected by Western blot. The analysis of
EGFR internalization followed the protocol developed by
Doyotte et al. [34] and Raiborg et al. [35]. Briefly, COS7
cells were transfected with CIN85 mutants. After 72 hours,
the cells were serum-starved overnight and incubated with
Alexa Fluor-labeled EGF (200 ng/ml in Eagle’s minimal
essential medium supplemented with 20 mM Hepes and
2 mg/ml bovine serum albumin) on ice for 30 minutes.
Cells were then washed with pre-warmed binding buffer
(37°C) three times and incubated in binding buffer for
indicated length of time before fixation with 4% PFA.Chemical cross-link by dimethylpimelimidate (DMP)
HEK293 cells expressing CIN85 mutants were lysed in
0.2 M triethanolamine (pH 8.0). 100 μM DMP was added
to the lysate and the mixture was incubated for 1 hour at
4°C. The cross-linking reaction was terminated by adding
100 mM Tris–HCl (pH 7.5). The samples were subjected
to SDS-PAGE for western blot.Abbreviations
CIN85: Cbl-interacting protein of 85 kDa; Cbl: Casitas B-lineage lymphoma
proto-oncoprotein; EGFR: Epidermal growth factor receptor; PA: Phosphatidic
acid; ESCRT: Endosomal sorting complex required for transport; CC: Coiled-
coil domain; SH3: Src homology domain; ΔCC: Coiled-coil domain deletion;
PRC: Proline-rich C-terminal region; Vps: Vacuolar protein sorting;
CHMP: Charged multivesicular body protein.Competing interests
The authors declare that they have no competing interests.Authors’ contribution
XZ performed plasmid construction, cell transfections, cell fractionation,
phosphatidic acid association, chemical cross-link, localization immunofluorescence,
immunoprecipitations, downregulation and internalization assay of EGFR, and
statistical analysis. JZ performed plasmid construction, cell transfections and
localization immunofluorescence. KL conceived of the study, participated in its
design and coordination and drafted the manuscript. The final manuscript was
read and approved by all authors.
Zheng et al. BMC Biochemistry 2014, 15:13 Page 11 of 11
http://www.biomedcentral.com/1471-2091/15/13Acknowledgements
This work was supported by the Ministry of Science and Technology of
China [grant numbers 2010CB912102], and the China National Nature
Sciences Foundation [grant numbers 31370818].
Author details
1From State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell
Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of
Sciences, Shanghai 200031, China. 2Current address: Department of
Hematology/Oncology, Johann Wolfgang Goethe University, R301 Haus 25
Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
Received: 14 April 2014 Accepted: 3 July 2014
Published: 8 July 2014References
1. Dikic I: CIN85/CMS family of adaptor molecules. FEBS Lett 2002, 529:110–115.
2. Take H, Watanabe S, Takeda K, Yu ZX, Iwata N, Kajigaya S: Cloning and
characterization of a novel adaptor protein, CIN85, that interacts with
c-Cbl. Biochem Biophys Res Commun 2000, 268:321–328.
3. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I: Cbl-CIN85-
endophilin complex mediates ligand-induced downregulation of EGF
receptors. Nature 2002, 416:183–187.
4. Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S: The
endophilin-CIN85-Cbl complex mediates ligand-dependent
downregulation of c-Met. Nature 2002, 416:187–190.
5. Schmidt MH, Hoeller D, Yu J, Furnari FB, Cavenee WK, Dikic I, Bögler O: Alix/
AIP1 antagonizes epidermal growth factor receptor downregulation by
the Cbl-SETA/CIN85 complex. Mol Cell Biol 2004, 24:8991–8993.
6. de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J: c-Cbl
ubiquitinates the EGF receptor at the plasma membrane and remains
receptor associated throughout the endocytic route. J Cell Sci 2001,
114:2167–2178.
7. Kowanetz K, Husnjak K, Höller D, Kowanetz M, Soubeyran P, Hirsch D,
Schmidt MH, Pavelic K, De Camilli P, Randazzo PA, Dikic I: CIN85 associates
with multiple effectors controlling intracellular trafficking of epidermal
growth factor receptors. Mol Biol Cell 2004, 15:3155–3166.
8. Schroeder B, Weller SG, Chen J, Billadeau D, Mark A, McNiven MA: A Dyn2-
CIN85 complex mediates degradative traffic of the EGFR by regulation of
late endosomal budding. EMBO J 2010, 29:3039–3053.
9. Dikic I, Giordano S: Negative receptor signaling. Curr Opin Cell Biol 2003,
15:128–135.
10. Dikic I, Szymkiewicz I, Soubeyran P: Cbl signaling networks in the
regulation of cell function. Cell Mol Life Sci 2003, 60:1805–1827.
11. Ronning SB, Pedersen NM, Madshus IH, Stang E: CIN85 regulates
ubiquitination and degradative endosomal sorting of the EGF receptor.
Exp Cell Res 2011, 317:1804–1816.
12. Reutens AT, Begley CG: Endophilin-1: a multifunctional protein. Int J
Biochem Cell Biol 2002, 34:1173–1177.
13. Kjaerulff O, Brodin L, Jung A: The structure and function of endophilin
proteins. Cell Biochem Biophys 2011, 60:137–154.
14. Haglund K, Shimokawa N, Szymkiewicz I, Dikic I: Cbl-directed
monoubiquitination of CIN85 is involved in regulation of ligand-induced
degradation of EGF receptors. Proc Natl Acad Sci U S A 2002, 99:12191–12196.
15. Katzmann DJ, Odorizzi G, Emr SD: Receptor downregulation and
multivesicular-body sorting. Nat Rev Mol Cell Biol 2002, 3:893–905.
16. Sorkin A, Goh LK: Endocytosis and intracellular trafficking of ErbBs.
Exp Cell Res 2009, 315:683–696.
17. Haglund K, Dikic I: The role of ubiquitylation in receptor endocytosis and
endosomal sorting. J Cell Sci 2012, 125:265–275.
18. Shen Y, Xu L, Foster DA: Role for phospholipase D in receptor-mediated
endocytosis. Mol Cell Biol 2001, 21:595–602.
19. Jenkins GM, Frohman MA: Phospholipase D: a lipid centric review. Cell Mol
Life Sci 2005, 62:2305–2316.
20. Donaldson JG: Phospholipase D in endocytosis and endosomal recycling
pathways. Biochim Biophys Acta 2009, 1791:845–849.
21. Lee CS, Kim KL, Jang JH, Choi YS, Suh PG, Ryu SH: The roles of phospholipase
D in EGFR signaling. Biochim Biophys Acta 2009, 1791:862–868.
22. Zhang J, Zheng X, Yang X, Liao K: CIN85 associates with endosomal
membrane and binds phosphatidic acid. Cell Res 2009, 19:733–746.23. Watanabe S, Take H, Takeda K, Yu ZX, Iwata N, Kajigaya S: Characterization
of the CIN85 adaptor protein and identification of components involved
in CIN85 complexes. Biochem Biophys Res Commun 2000, 278:167–174.
24. Burkhard P, Stetefeld J, Strelkov SV: Coiled coils: a highly versatile protein
folding motif. Trends Cell Biol 2001, 11:83–88.
25. Jouvenet N: Dynamics of ESCRT proteins. Cell Mol Life Sci 2012, 69:4121–4133.
26. Williams RL, Urbe S: The emerging shape of the ESCRT machinery. Nat Rev
Mol Cell Biol 2007, 8:355–368.
27. Yoshimori T, Yamagata F, Yamamoto A, Mizushima N, Kabeya Y, Nara A,
Miwako I, Ohashi M, Ohsumi M, Ohsumi Y: The mouse SKD1, a homologue
of yeast Vps4p, is required for normal endosomal trafficking and
morphology in mammalian cells. Mol Biol Cell 2000, 11:747–763.
28. Fujita H, Yamanaka M, Imamura K, Tanaka Y, Nara A, Yoshimori T, Yokota S,
Himeno M: A dominant negative form of the AAA ATPase SKD1/VPS4
impairs membrane trafficking out of endosomal/lysosomal
compartments: class E vps phenotype in mammalian cells. J Cell Sci 2003,
116:401–414.
29. Szymkiewicz I, Kowanetz K, Soubeyran P, Dinarina A, Lipkowitz S, Dikic I:
CIN85 participates in Cbl-b-mediated down-regulation of receptor
tyrosine kinases. J Biol Chem 2002, 277:39666–39672.
30. Philippe D, Ababou A, Yang X, Ghosh R, Daviter T, Ladbury JE, Pfuhl M:
Making Ends Meet: the importance of the N- and C-termini for the
structure, stability, and function of the third SH3 domain of CIN85.
Biochemistry 2011, 50:3649–3659.
31. Kowanetz K, Szymkiewicz I, Haglund K, Kowanetz M, Husnjak K, Taylor JD,
Soubeyran P, Engstrom U, Ladbury JE, Dikic I: Identification of a novel
proline-arginine motif involved in CIN85-dependent clustering of Cbl
and down-regulation of epidermal growth factor receptors. J Biol Chem
2003, 278:39735–39746.
32. Bache KG, Stuffers S, Malerød L, Slagsvold T, Raiborg C, Lechardeur D,
Wälchli S, Lukacs GL, Brech A, Stenmark H: The ESCRT-III subunit hVps24 is
required for degradation but not silencing of the epidermal growth
factor receptor. Mol Biol Cell 2006, 17:2513–2523.
33. Huo H, Guo X, Hong S, Jiang M, Liu X, Liao K: Lipid rafts/caveolae are
essential for insulin-like growth factor-1 receptor signaling during 3 T3-L1
preadipocyte differentiation induction. J Biol Chem 2003, 278:11561–11569.
34. Doyotte A, Mironov A, McKenzie E, Woodman P: The Bro1-related protein
HD-PTP/PTPN23 is required for endosomal cargo sorting and multivesi-
cular body morphogenesis. Proc Natl Acad Sci U S A 2008, 105:6308–6313.
35. Raiborg C, Bache KG, Mehlum A, Stang E, Stenmark H: Hrs recruits clathrin
to early endosomes. EMBO J 2001, 20:5008–5021.
doi:10.1186/1471-2091-15-13
Cite this article as: Zheng et al.: The basic amino acids in the coiled-coil
domain of CIN85 regulate its interaction with c-Cbl and phosphatidic
acid during epidermal growth factor receptor (EGFR) endocytosis. BMC
Biochemistry 2014 15:13.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
